Cyclacel Pharmaceuticals Inc Share Price Nasdaq
Equities
US23254L3069
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
30/04 | Top Midday Gainers | MT |
30/04 | Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of FOMC Meeting | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.79M 150M |
---|---|---|---|---|---|
Net income 2024 * | -23M -1.92B | Net income 2025 * | -26M -2.17B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.1
x | P/E ratio 2025 * |
-0.06
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.05% |
Latest transcript on Cyclacel Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 01/97/01 |
Paul McBarron
DFI | Director of Finance/CFO | 63 | 01/02/01 |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 17/20/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 83 | 01/06/01 | |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 17/20/17 |
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 01/97/01 |
1st Jan change | Capi. | |
---|---|---|
-3.46% | 102B | |
+1.41% | 96.29B | |
+2.13% | 22.18B | |
-15.84% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.65% | 16.36B | |
+4.39% | 13.97B | |
+31.35% | 12.17B |